ozanimod + gemfibrozil

A combination of **ozanimod**, a selective sphingosine 1-phosphate (S1P) receptor modulator, and **gemfibrozil**, a lipid-lowering agent and strong inhibitor of cytochrome P450 2C8 (CYP2C8). Ozanimod binds S1P receptors 1 and 5, preventing lymphocytes from exiting lymph nodes, reducing peripheral blood lymphocytes, and is approved for treatment of relapsing multiple sclerosis and moderately to severely active ulcerative colitis. Gemfibrozil, a fibrate, is used for dyslipidemia and serves here as a strong CYP2C8 inhibitor. This drug combination is not intended for therapeutic use; instead, it has been used in clinical pharmacology studies to assess the effect of CYP2C8 inhibition on the pharmacokinetics of ozanimod and its active metabolites. Coadministration increases exposures of ozanimod active metabolites (CC112273 and CC1084037) but does not significantly affect ozanimod itself, and is not recommended clinically due to increased metabolite exposure[1][2][4].

Other names

ozanimod + gemfibrozil